Drug Trial Radar · NCT04045769
A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Aug 19, 2019
Primary completion
Nov 27, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
Conditions
- Healthy
Interventions
Saroglitazar magnesium 4mgDrug
1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
PlacebosDrug
5 tablets of placebo to be administered orally
Moxifloxacin 400mgDrug
1 tablet of 400 mg Moxifloxacin to be administered orally
Saroglitazar magnesium 20 mgDrug
5 tablets of 4 mg Saroglitazar magnesium to be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- QTcF change-from-baselineTime frame: Pre-dose (-1.0 hr) to 24 hours post dose
- Saroglitazar and its metabolite saroglitazar sulfoxide plasma concentrations and placebo-corrected change-from-baseline QTcFTime frame: Pre-dose (-1.0 hr) to 24 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research Limited
Ahmedabad, Gujarat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.